###### Strengths and limitations of this study

-   Short time interval between the visits (every 2 months for infected women) and additional self-sampling every week at home.

-   The combination of virological (virus load), immunological (cytokine concentrations and immune cell percentages) and environmental (vaginal microbiota composition, pH) measurements at each visit.

-   A limitation is that the density of the follow-up limits the number of participants (n=150) which can affect the power of epidemiological analyses.

-   We complement the longitudinal study with a cross-sectional study of n=150 women to increase statistical power.

Introduction {#s1}
============

Epidemiology of human papillomavirus genital infections in young adults and public health implications {#s1a}
------------------------------------------------------------------------------------------------------

Infections by human papillomaviruses (HPVs) are likely the most common sexually transmitted infection (STI) globally. It is often estimated that, worldwide, more than 80% of sexually active individuals will be infected by an HPV type.[@R1] In France, a study performed in 2013 in the Paris area estimated the prevalence of HPV genital infections to be 25% in women below 25 years of age.[@R3] In the area of Montpellier (France), the prevalence of oncogenic HPVs (also referred to as 'high-risk' (HR) HPVs) in pregnant women aged 16--42 years was close to 20%.[@R4] These numbers are consistent with worldwide estimates according to which HPVs are most prevalent in women under 25 years of age, with an estimated overall prevalence of 24%.[@R5]

Fortunately, the vast majority of infections by HPVs are asymptomatic and benign. Even for HPV16, which is probably the most oncogenic human virus, only a minority of infections (less than 10%) become persistent,[@R6] and then a minority of these (12%) progress to cancer if untreated.[@R1] Indeed, it is estimated that approximately 70%--100% of infections by HPVs are cleared within 12--24 months, with strong differences between virus types.[@R6] Recent studies suggest that primo-infections could be shorter in young girls[@R11] but, in general, there are many unknowns about the biology of non-persisting infections.[@R12]

Our lack of knowledge partly comes from the fact that in vaccine trials, from which most of the data on infection duration originate, participants are followed every 6 months for several years.[@R6] This frequency is sufficient to estimate the time to clearance (or persistence) but it is not precise enough to understand the within-host dynamics, often referred to as 'kinetics',[@R14] of infections that last on average 6--24 months. Arbitrarily, after 24 months, an infection is often considered to be persistent.[@R15]

Some factors have been shown to correlate with persistence (eg, immunosuppression, smoking and co-infection with other STIs[@R16]) but we do not know how these affect viral kinetics. Also, some changes in the interactions between virus and the host immunity appear to be related to persistence and disease progression[@R17] but, again, we do not know the underlying interactions between the viruses, the host target cells, and the immune response in acute infections.[@R12] Finally, it has been argued that the vaginal microbiota may differ between HPV-infected and HPV-uninfected women[@R21] and that specific microbiota composition may interact with HPV detection.[@R22] However, it is difficult to disentangle the cause and the consequence. For instance, does the microbiota composition change after the establishment of an HPV infection, or do certain microbiota compositions increase susceptibility to HPV infection?

A better understanding of the within-host infection dynamics and of the determinants of clearance and persistence of viral infection is particularly important in the context of vaccination.[@R23] Indeed, the long-term efficacy of the anti-HPVs vaccines at the population level will largely depend on the within-host viral dynamics because, ultimately, most selective pressures on viral populations occur via the immune response.[@R27] Furthermore, a better understanding of acute HPV infections can shed new light on issues related to latency, fertility or immunotherapies.[@R12]

Prevention strategies and treatment {#s1b}
-----------------------------------

### Treatment {#s1b1}

Since most infections by HPVs are benign in young adults and clear within six to 24 months, the current standard of care is to avoid over-treatment, even in the presence of cervical lesions.[@R28] Clinical interventions (colposcopies, biopsies and surgery) are less often performed with young women (*\<*25 years) and only for high-grade (precancerous) lesions (cervical intraepithelial neoplasia grade 2 (CIN-2) or more). Low-grade lesions (CIN-1) are not systematically treated but rather monitored yearly to detect any progression to high-grade lesions.

Genital warts caused by non-oncogenic HPVs (often referred to as 'low-risk' (LR) HPVs) can be removed by surgery or treated with bi- and trichloroacetic acid, cryotherapy or other treatments.[@R29]

### HPV vaccination {#s1b2}

There are currently three licensed vaccines: a bivalent vaccine (Cervarix) targeting HPV16 and HPV18 (together accounting for 70% of cervical cancers[@R1]), a quadrivalent vaccine (Gardasil) that additionally targets HPV6 and HPV11 (non-oncogenic, but highly prevalent and associated to benign proliferative lesions) and, since 2014, a nonavalent vaccine (Gardasil 9) that targets five more oncogenic types (HPV31, HPV33, HPV45, HPV52 and HPV58, which altogether account for 20% of cervical cancers[@R25]). These vaccines succeed in eliciting a protective immune response against new infections by the targeted viruses, and are used throughout the world, although with wide variation in coverage (for reviews, see, e.g, refs[@R30]).

Vaccination campaigns in France started in 2006 but with limited coverage: it reached 28.5% in 2008[@R32] and has been decreasing ever since.[@R33] The vaccine is recommended for girls from 11--14 years of age, currently with a vaccination scheme of two doses with a 6-month interval. A catch-up is organised for girls aged 15--19 years, with a three-dose vaccination scheme. Vaccination is reimbursed by the French Social Security but is not mandatory. It is also recommended for men who have sex with men as well as for immuno-compromised people.[@R33] Vaccination is now the primary prevention strategy against cervical cancers.

### Screening {#s1b3}

In France, the secondary prevention strategy against cervical cancer is routine individual cytology-based screening for precancerous and cancerous cervical lesions in women between 25 and 65 years old. Cytology can also be performed in younger women if they report risk factors for cervical cancer (multiple partners, chronic STIs or HIV infection[@R33]). Detection of oncogenic HPVs is proposed for triage in case of abnormal cytology (ie, high-grade or low-grade squamous intraepithelial lesion (HSIL and LSIL, respectively) or atypical squamous cells of undetermined significance (ASCUS)).

Primary objectives {#s1c}
------------------

The first primary objective of this cohort study is to decipher the kinetics and ecology of cervical HPV infections in healthy young women, that is, follow the population dynamics of the virus, the target epithelial cells, the vaginal microbiota, and the immune effectors.

The second primary objective is to characterise the diversity of genital HPVs in young women in the region of Montpellier in relationship with their lifestyle, vaccination status, vaginal microbiota and human genetics.

Secondary objectives {#s1d}
--------------------

A secondary objective is to characterise the acquisition and clearance dynamics of cervical HPV infections as a function of viral diversity, host immunity, vaginal microbiota and human genetics.

A final objective is to investigate variations in genetic diversity of HPVs during cervical infections.

Methods and analysis {#s2}
====================

Participants {#s2a}
------------

The study population is composed of young women at risk of HPV infection. The age class was chosen because it exhibits high HPV prevalence (24% worldwide[@R5] and approximately 25% in France[@R3]). Inclusion of younger women would have raised technical issues because of the requirement for parental consent.

Women are recruited through a social media page, and through posters and leaflets distributed at the universities in Montpellier and at the Montpellier STI screening centre (*Centre Gratuit d'Information de Dépistage et de Diagnostic*, CeGIDD). The composition of the population visiting the CeGIDD has already been documented in an earlier study.[@R34] In total, the centre is visited by approximately 3,000 women per year, the majority of which are under 25 years of age (80%). Approximately 40% of the attendants report three or more partners over the last 12 months and approximately 50% report using adequate behaviour for prevention against HIV.

Since all participants are healthy, they are referred to as participants rather than patients. As in any longitudinal study, ensuring participant commitment is challenging. To achieve this goal, we have set up a compensation of €40 per visit and an additional €10 in case of a complete follow-up. Furthermore, participants who have answered a sufficient number of questionnaires and brought back a sufficient number of self-samples get a €100 bonus at the end. Overall, a participant performing 12 return visits would gain a total compensation of €650.

Inclusion criteria {#s2b}
------------------

Participants are women from 18 to 25 years old living in the metropolitan area of Montpellier. They must be sexually active with at least one new partner over the last 12 months. These criteria are fixed to maximise the incidence of new HPV infections. Participants must be able to and willing to give written informed consent: they must sign an informed consent form, understand the requirements for the study and be affiliated to a French social security scheme (which is a state requirement).

Women cannot be included in the study if they have a history of HPV-associated pathology (genital warts or cervical lesions), if they are pregnant or intending to become pregnant in the coming year, infected by HIV, undergoing (or planning to undergo) intense medical treatment (biotherapy, chemotherapy, immunosuppression), planning on moving outside the Montpellier metropolitan area within the next 18 months, in a dependency or employment with the sponsor or the investigator, if they participated in a clinical trial involving administration of drugs within the last 4 weeks or if they belong to a vulnerable group (e.g., children, adults with physical or mental disabilities).

Design/setting {#s2c}
--------------

This study has a longitudinal component aimed at deciphering within-host dynamics and a cross-sectional component aimed at understanding the diversity of HPV infections in young adults in the area of Montpellier, France. The general structure of the study is shown in [figure 1](#F1){ref-type="fig"}.

![General structure of the PAPCLEAR study. For the longitudinal study, participants have an inclusion visit (*V* ~1~), a results visit (*V* ~2~) and then return visits (V*i* with *i*\>2). For the cross-sectional study, participants only have *V* ~1~ and *V* ~2~. HPV, human papillomavirus; STI, sexually transmitted infection.](bmjopen-2018-025129f01){#F1}

If a woman fits the main inclusion criteria, she can go through an inclusion visit (*V* ~1~) with a physician (gynaecologist or midwife) at the CeGIDD. During this visit, the study investigator presents the study and checks all inclusion criteria before asking the participant to read and sign the informed consent form. Participants then undergo a medical consultation during which a number of samples are collected (see below). They then fill out health and lifestyle questionnaires and are given cotton-flocked swabs for self-sampling at home the next visit, along with instructions on how to fill in weekly questionnaires through an online form (these are performed throughout the study).

An appointment is scheduled 4 weeks later for the results visit (*V* ~2~), where the cervical cytology results are communicated. Additional samples are collected and self-sample swabs for home collection are provided.

The next return visits (*V~i~*, where *i\>*2) are as follows:Participants with a positive HPV detection test (see below), that is, infected by an *Alphapapillomavirus*, at *V* ~1~ join the HPV positive (HPV+) arm of the study with return visits scheduled every 2 months.Participants with a negative HPV detection test at *V* ~1~ join the HPV negative (HPV-) arm with return visits scheduled every 4 months.HPV- participants infected by an *Alphapapillomavirus* move to the HPV+ arm.

Intervals between visits are based on earlier results showing that HPV infections last from 9 to 18 months on average depending on the HPV type[@R6] and that a total follow-up of 4 months yields results that are difficult to analyse.[@R22] The longer interval in the HPV- arm is based on the estimated incidence for HPV genital infections in young women which is greater than 30%.[@R35]

Participants in the HPV- arm are followed until month 32 of the study.

Participants in the HPV+ arm are followed until they clear the infection or until they have been infected for 24 months (after which we consider that the infection is persistent). Clearance is defined as being negative at two visits in a row for the first HPV type detected in the follow-up.

In between these visits to the CeGIDD, participants are asked to perform regular (every week for HPV+ and every second week for HPV-) self-samples using vaginal swabs (every week for HPV+ and  every second week for HPV-), to measure vaginal pH and to fill in a short questionnaire. Self-samples are stored in the participants' freezer and brought back at every visit.

The study will end with the last HPV+ participant having cleared the infection or been infected for 24 months.

Patients and public involvement {#s2d}
-------------------------------

Participants did not play a role in the design of this study and the results of the study will be disseminated to participants who have left the study and to the general public via an email newsletter in French.

Visits {#s2e}
------

The summary of the visit schedule and of the samples collected at each visit is shown in [table 1](#T1){ref-type="table"}.

###### 

Summary of the visit schedules and samples take

  Participants                                            Inclusion (*V* ~1~)   Results (*V* ~2~)   Return (*V~i~*, with *i\>*2)   
  ------------------------------------------------------- --------------------- ------------------- ------------------------------ -----------
  Time                                                    Day 0                 +4 weeks            +8 weeks                       +16 weeks
  Eligibility                                             ¤                                                                        
  Consent                                                 ¤                                                                        
  Gynaecological consult                                  ¤                     ¤                   ¤                              ¤
  Vaginal pH cotton swab                                  ¤                     ¤                   ¤                              ¤
  two vaginal swab samples (Copan ESwab)                  ¤                     ¤                   ¤                              ¤
  One ophthalmological sponge sample                      ¤                                         ¤                              ¤
  One cervical smear in PreservCyt (cytology)             ¤                                         \+                             
  One cervical smear in PBS (Phosphate Buffered Saline)                         ¤                   \+                             ¤
  Blood sampling (HPV antibodies)                         ¤                                         ¤                              
  Blood sampling (sequencing)                             ¤                                                                        
  Blood sampling (immunophenotyping)                      ¤                                         ⊲                              
  Other STI detection                                     ⋆                     ⋆                   ⋆                              ⋆
  Questionnaire \#1 (inclusion)                           ¤                                                                        
  Questionnaire \#2 (visit)                                                     ¤                   ¤                              ¤
  Questionnaire \#3 (home)                                ¤                     ¤                   ¤                              ¤
  Returning self-sampling samples                                               ¤                   ¤                              ¤
  Serious adverse event collection                                              ¤                   ¤                              ¤

The cross-sectional study only includes the first two columns (*V* ~1~ and *V* ~2~). ¤ S amples taken at visits. + P articipants infected by a HR-HPV for 12  month will have one PBS smear replaced by a Thinprep smear to perform a cytology and check for lesions. ⊲ T his sample is only taken at the first HPV + visit of a formerly HPV- participant. ⋆ STI detection will be performed at inclusion unless the participant has been tested within the last 3 months and during the study every 6 months if a new partner has been reported or request. HPV, human papillomavirus; STI, sexually transmitted infection.

### Inclusion visit (*V* ~1~) {#s2e1}

This visit takes place at the CeGIDD and is scheduled by the Clinical Research Technician (CRT) via phone or email.

Women meet a study investigator, who explains the goals and requirements of the study and checks that the inclusion criteria are met. If so, after a general discussion, the informed consent forms are signed.

A female physician/midwife performs a general exam and then a gynaecological exam during which the following samples are taken:Vaginal pH cotton swab (EcoCare).Vaginal swab (Copan ESwab) in 1 mL Amies liquid for DNA extraction and microbiota analysis.Vaginal swab (Copan ESwab) in 1 mL of RNA preservation medium.Ophthalmic sponge (Weck-cel) to collect cervical secretions for cytokines analysis.Cervical smear in 20 mL of PreservCyt liquid (Thinprep test) for HPV and HSV assays, and cytology evaluation.

Following the gynaecological consultation, the participant meets with a nurse to measure body temperature, blood pressure and draw 20 mL of blood (a 5 mL tube for single nucleotide polymorphisms (SNP) genotyping, a 10 mL tube for immunophenotyping and a 5 mL tube for HPV antibody titration). For the longitudinal study, the nurse provides the participant with three self-sampling kits, three pH strips, a freezer box to bring back to the next visit and instructions on how to perform the home sampling and store the samples in her personal freezer until the next visit.

If the participant has not been tested for STIs in the last 3 months, the nurse draws an additional blood tube of 5 mL to test for STIs (HIV, hepatitis C virus, hepatitis B virus) and collects vaginal self-samples for chlamydiae and gonorrhoea detection. Syphilis testing is prescribed to participants who meet the STI clinic's guidelines.

Finally, the participant meets with the CRT to fill in questionnaires \#1 (inclusion visit) and \#3 (home). The CRT answers any remaining questions, explains how to fill the home questionnaires (\#3) and sets an appointment for the Results visit.

### Results visit (*V* ~2~) {#s2e2}

During this visit, the participants are given the result of cervical lesion screening using the liquid cytology (normal, ASCUS, LSIL or HSIL). Participants with a high-grade lesion (HSIL) exit the study and are referred to the gynaecology service of the Centre Hospitalier Universitaire (CHU) of Montpellier.

During this visit, the physician/midwife collects additional samples: two vaginal swabs for DNA and RNA analysis, and a cervical smear in 5 mL of PBS (to confirm HPV status and perform flow cytometry analyses).

The participant fills in questionnaires \#2 (for return visits) and \#3 (home). An appointment for the next visit is set and swabs for home self-sampling are given.

### Return visits (*V~i~*) {#s2e3}

These visits only occur in the longitudinal study.

#### HPV- arm {#s2e3a}

Participants uninfected by HPV visit the clinic every 4 months until month 26. During these visits, the same samples as in the inclusion visit (*V* ~1~) are collected by the physician/midwife except for the cervical smear, which is put in PBS instead of Thinprep.

The nurse only draws blood if a screening test for STIs other than HPV is required. The participant then fills in questionnaires \#2 and \#3 and an appointment is set for the next visit in 16 weeks.

If an HPV infection is detected in the cervical smear collected during this visit, the participant moves to the HPV+ arm and the CRT contacts the participant to move her appointment forward.

#### HPV+ arm {#s2e3b}

Participants infected by HPV visit the clinic every 2 months. They cannot switch arm and will remain in the HPV+ arm until clearance or the end of the study. During the visits, the same samples as in the inclusion visit (*V* ~1~) are collected by the physician/midwife except for the cervical smear, which is put in PBS instead of PreservCyt.

The nurse then draws 5 mL of blood for HPV antibody titration. If this is the first HPV+ visit following an HPV- visit, the nurse also draws 10 mL of blood for immunophenotyping. Finally, if a test for additional STIs is needed, the nurse draws 5 mL of blood and collects vaginal self-samples for STI detection.

Importantly, if the participant has been infected by a HR-HPV for more than 12 months and a cytological analysis has not been performed within the last 12 months, the cervical smear is put in PreservCyt fixation medium, instead of PBS, for cytological analysis (cervical lesion screening).

Finally, the participant fills in questionnaires \#2 and \#3, receives self-samples for home collection and an appointment is set for the next visit in 8 weeks.

Endpoints {#s2f}
---------

The primary endpoint for the study is the inclusion and follow-up of HPV-infected women in order to describe the kinetics of HPV virus load, and the associated immune response.

Secondary endpoints are the characterisation of the interactions between the course of the infection (eg, duration), the HPV type(s), the abundance and taxonomic diversity of bacteria, fungi and viruses in the vaginal microbiota, human genetics (SNPs) and basal immunological status.

Technical procedures {#s2g}
--------------------

### DNA extraction {#s2g1}

DNA extraction from cervical smears will be performed using Nuclisens easyMAG from Biomerieux or an equivalent protocol. For the microbiota analyses, special kits involving physical (via beads) and/or enzymatic breaking of the cellular barrier will be favoured following standard protocols to study the vaginal microbiome,[@R37] for example, the MagAttract PowerMicrobiome DNA/RNA kit from Qiagen.

### HPV detection, typing and quantification {#s2g2}

The participants' infection status (HPV+ or HPV-) will be assessed using a DNA enzyme immunoassay (DEIA) detection test based on a PCR of the short SPF~10~ amplicon[@R38], which detects all *Alphapapillomaviruses* with great sensitivity.

If the DEIA test is positive, HPVs will be typed using the LiPA25 kit which is based on the same SPF~10~-PCR, and has a lower detection threshold compared with other hybridisation-based typing methods.[@R39]

The reason for basing the detection on the DEIA rather than the LiPA25 is that some *Alphapapillomavirus* may be detected by DEIA but not genotyped by LiPA and also that the DEIA is more sensitive than the LiPA. If the DEIA is positive and the LiPA25 is negative, typing will be performed by sequencing the product of a PGMY09/11 PCR[@R40] which targets another region of the HPV genome than the SPF10 PCR.

The quantification of HPV DNA genome copy number in the samples will be performed using the qPCR protocol set up by Micalessi *et al*.[@R41]

### Cytokine titration {#s2g3}

Cytokines can be used as markers of immune activation or immunosuppression and can also inform us on which components of the immune system are involved. Cervical sponges are centrifuged after the addition of 175µL of PBS. Cervical secretions are analysed for a set of 5 to 6 cytokines levels using the Meso Scale Discovery Multiplex ELISA platform which has a low detection threshold and a slowly saturating dose--response curve. Based on earlier results,[@R42] we will first investigate a large panel of 20 cyctokines to choose the most relevant ones for a longitudinal follow-up.

### Flow cytometry {#s2g4}

Analysing immune cells via flow cytometry is extremely challenging on cells as fragile as the ones from cervical smears. However, several studies suggest that this is feasible.[@R42] Here, we follow the protocol described in Ref [@R45].

Staining is performed using a Duraclone custom mix targeting CD45, CD3, CD4, CD8, CD16, CD56, CD69, CD161 and TCR*γδ*. The last marker, Live&Dead tests for cellular viability. Samples are acquired using a Navios flow cytometer (Beckman Coulter, three-laser configuration).

### Sequencing {#s2g5}

Sequencing will be performed for microbiota profiling. It involves PCR amplification of the V3-V4 region of 16S RNA for bacteria[@R46] and ITS1 for fungi.[@R47] We anticipate that the bacteria should belong to the operational taxonomic units (OTU) described in the five community state types found in vaginal communities.[@R48] The virome will also be explored using shotgun sequencing and rolling circle PCR amplification.[@R50] Human genetics are explored using chip sequencing for SNPs.

Statistical analyses {#s2h}
--------------------

### Times series analyses {#s2h1}

The core results of the study will come from the longitudinal follow-up of infected women which will generate time series (ie, a set of values collected from the same individual over time) ([figure 2](#F2){ref-type="fig"}). There will be several time series per individual (virus load, number of immune cells, cytokine and antibody levels). These time series will be used to fit mathematical viral kinetics models that describe the interaction between viruses, host target cells (here, in the case of HPV, keratinocytes) and the immune response. These models are commonly developed for viral infections,[@R14] including those caused by HPVs.[@R54] We anticipate our follow-up to yield adequate data for such a fit based on the estimated duration of HPV infections (9--18 months[@R6]). Furthermore, the weekly self-samples allow us to increase the resolution if necessary.

![Fitting viral kinetics models to within-host times series. Dashed lines indicate a model fitted using virus load (in black) or immune cells (in red) time series. In panel A, the follow-up is bi-monthly with two missing visits and several delayed visits, whereas in panel B the follow-up is every 4 months without any missing or delayed visits. In spite of missing data this, the situation shown in panel A is clearly the best for inferring parameter values and for fitting the underlying dynamics.](bmjopen-2018-025129f02){#F2}

We will use non-linear mixed effect models[@R55] to jointly analyse time series from all participants. More precisely, we will rely on *R* packages such as nlme[@R56] or lme4.[@R56] Note that, in addition to estimating model parameters (eg, life-expectancy of infected cells or virion production rate of infected cells), this approach also allows us to compare biological models using statistical tools based on model likelihood such as Akaike Information Criterion. For an example of such analysis in the case of HIV, see Ref.[@R52]

### Microbiota dynamics {#s2h2}

The composition of the vaginal microbiota has already been described and shown to exhibit considerably less diversity than the gut microbiota.[@R48] The dynamics of this microbiota has also been studied and shown to closely follow menstrual cycles.[@R49]

Using the time series of OTU abundances (measured via 16S RNA sequencing and qPCR) we will infer interaction parameters by assuming an underlying Lotka-Volterra competition model.[@R57] This work will include time series analysis techniques (eg, auto-correlation or local similarity analysis) and statistical inference methods in order to infer community structure and interactions from the next-generation sequencing (NGS) datasets.[@R58] Finally, statistical methods from ecology will also be used to study community diversity (eg, diversity indices) and community assembly, such as cluster and ordination analyses.[@R59]

### Genome wide association studies {#s2h3}

We will use human SNPs inferred by chip sequencing to look for genetic determinants of key traits (e.g., microbiota composition or HPV infection duration). This is classically done by performing a Genome Wide Association Study (GWAS), which is a complex regression method designed for situations where there are many explanatory variables (here millions of SNPs) for a single trait of interest. GWAS will be performed using classical methods.[@R60] Earlier GWAS studies have been applied to HPV infections for instance to test for determinants to the ability to seroconvert following infection[@R61] and cervical cancer (see[@R62] for a review). Here, our expected sample (n=300 women) is limited but SNPs with large effects have been detected by studies with comparable sizes.[@R63]

### Additional analyses {#s2h4}

For all collected variables, descriptive statistics will be calculated according to the level of measurement. For metric variables these statistics can be mean and SD as well as quantiles and more robust statistics.[@R64] In case of categorical variables group proportions and contingency tables are prepared.

Univariate inferential statistics follow a descriptive analysis. Generally, parametric testing procedures are preferred to non-parametric tests, as the former have higher power. That is why, for metric variables, we will first check whether the data can be assumed to be normally distributed. For normally distributed variables, analysis of variance statistics are done to detect differences between groups. In case of significance, post-hoc analysis (Tukey test) are planned to reveal pairwise differences. If the data are not normally distributed or ordinally scaled, non-parametric analyses will be used. These contain the Kruskal-Wallis test and the Wilcoxon test as a post-hoc test with an appropriate correction of the significance level. Since the cell counts are expected to be small, Fisher's exact test will be performed for contingency tables instead of the asymptotic *χ* ^2^ test for categorical variables.

Sample size calculation {#s2i}
-----------------------

The study will enrol a total of n=300 women, with n=150 in a longitudinal study and n=150 in a cross-sectional study. The goal of the longitudinal study is to follow 75 women longitudinally, preferentially before they are infected (see above). For the following calculations, we assumed a high percentage of lost during follow-up (30%).

With 150 enrolments and considering that the prevalence of HPV infection in young women is ≈60% (based on our preliminary data) and 30% of lost to follow-up, we expect to detect (and successfully follow) 63 infections at inclusion (95% CI: 51 to 75, assuming a binomial distribution to calculate the 95% CI).

Among women who are uninfected at the first visit and considering the yearly incidence being close to 30%,[@R65] we expect 12 (95% CI 6 to 20) to be infected during the first year of follow-up (still assuming 30% of lost to follow-up).

In the end, with 150 enrolments and assuming a high percentage of lost to follow-up (30%), we expect to successfully follow 75 (95% CI 56 to 95) women infected at different stages of HPV infection: beginning, during and end.

This will be made possible by the probability of transmission of HPV, which is estimated to be ≈90% without condom use and still high with condom use (≈40%).[@R35]

Finally, regarding potential interference with the HPV vaccines, we do not anticipate any significant problem for two reasons. First, as mentioned above, the vaccine coverage is low in France.[@R33] Second, and more importantly, the vaccines only target few HPV types, thus leaving open the possibility of infection by dozens of types. Furthermore, studying the kinetics of a non-vaccine HPV type in a vaccinated woman will be extremely informative (eg, to detect any potential cross-reactivity).[@R66]

To run cross-sectional analyses (especially on the microbiota and human genetics), we will enrol n=150 additional women who will only perform the inclusion and the results visits. This sample size was chosen to reach that of earlier GWAS studies.[@R62]

Trial governance {#s2j}
----------------

### Sponsor {#s2j1}

This study is sponsored by the CHU of Montpellier. The CHU is involved in the implementation of the trial, legal/ethical submissions (see Ethics approval statement) and implementing the clinical database online Case Report Form (eCRF) which is hosted by Ennov-Clinical (ClinSight). The CHU is not involved in the analysis or interpretation of the data. The CHU of Montpellier performs regular quality control assessments. A clinical research assistant will visit the CeGIDD every 4 months to ensure that implementation is in accordance with the protocol. The CHU has taken out insurance from the Société hospitalière d'assurances mutuelles, 18, rue Edouard Rochet-6 9372 Lyon cedex 08 (contract number 138983) through the full research period, covering its own civil liability and that of any agent (clinical or research staff), in accordance with article L.1121--10 of the French Public Health Code.

### Scientific committee {#s2j2}

The scientific committee comprises the study investigators, clinicians, scientific experts and representatives of the sponsor. The committee meets yearly and is responsible for following research progress, monitoring compliance with good clinical practices and patient safety. It can also decide relevant modification of the protocol. Requests from third parties to access data collected during the study will be evaluated by the committee.

### Monitoring {#s2j3}

Monitoring is performed during the whole study at CeGIDD according to the sponsor specific SOP. Routine monitoring visits are made by the monitors designated by the sponsor to check compliance with the protocol, the completeness, accuracy and consistency of the data and adherence to GCP. The principal investigator ensures that eCRFs are completed in a timely manner and must allow periodical access to eCRFs, patient records, drug logs and all other study-related documents and materials. The frequency of monitoring visits is determined by factors such as study design and the site enrolment requirements but visits will normally occur at least once every 4 months.

Ethics and dissemination {#s2k}
------------------------

The protocol has been modified since its initial version and the latest modification was accepted by the Comité de Protection des Personnes on 12 December 2018.

All participants in the study will sign an informed consent form prior to participation.

The results will be published on preprint servers (eg, BioRxiv), peer-reviewed journals, postprint servers (e.g., *[Hyper Articles en Ligne](https://fr.wikipedia.org/wiki/Hyper_articles_en_ligne)*, HAL) and disseminated through conferences.

Discussion {#s3}
==========

Expected results {#s3a}
----------------

Acute infections by HPVs are important to study because vaccination is most effective when performed before the first infection. However, we currently know very little about the early stages of HPV infections. This clinical study will give us an unprecedented level of detail into the natural history of HPV infections in young women. Variations in virus load over time have been studied but in the context of cervical cancer in older women.[@R67] In addition, we will also describe the nature and the dynamics of the immune response (local immune cells and cytokines, circulating anti-HPV antibodies) and of the vaginal microbiota. Beyond these kinetics, we will also have access to data such as infection clearance or not in 24 months, presence of more than one HPV type or coinfection by other STIs.

These data will be analysed in the light of numerous cofactors. One of the most important will be human genetics, with the sequencing of millions of SNPs. Others will be related to the sexual behaviour (number of partners, contraception methods, sexual practices) and general lifestyle. We, therefore, expect broader insights regarding sexual health in young women.

Practical and operational issues {#s3b}
--------------------------------

One of the main practical challenges resides in the analysis of cervical smears by flow cytometry. Indeed, the tissues are known to be fragile, adhesive and auto-fluorescent. Even though standard protocols now exist,[@R45] they require processing fresh samples in less than 2 hours.

Another potential issue has to do with contamination by HPV DNA between samples, which are frequent in the HPV field due to the robustness of the virions and the sensitivity of the tests. To certify our ability to control for these, we have entered the 2017 GLOBAL HPV DNA Proficiency Panel from the WHO HPV LabNet.[@R68]

Regarding the enrolment of the participants, we do not expect issues with enrolling 150 women in 28 months for the longitudinal study and 150 for the cross-sectional study. This is due to the number of visitors of the centre who fit the inclusion criteria (more than 3000 per year) and because of earlier high participation rates in the same population ([@R34] enrolled 1381 participants in 5 months for their study).

Concerning the follow-up, the high incidence rate of HPV can also lead to transient carriage, that is, women who are positive for a type only at a single visit. This has been observed for instance in longitudinal studies with a tight follow-up interval.[@R22] To control for this, we will run the HPV detection test on the cells from the cervical smear after washing with RPMI.

Trial status {#s3c}
------------

The study began on 1 October 2016 and the first inclusion was on 3 November 2016. On 23 June 2018, 89 participants have been included in the longitudinal study. Inclusions in the longitudinal study will continue until March 2019 and the study is expected to last until August 2021.
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